Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat.

Abstract

This report is concerned with therapeutic studies utilizing new bisphosphonic acids on tumor-induced osteolytic metastases. The bone metastases on SD rats were induced by intraarterial and intraosseous transplantation of Walker carcinosarcoma 256 B ascites cells. The treatment was carried out using disodium-3-amino-1-hydroxypropylidene-1,1-bisphosphonate (ADP), diglycidyl-[3-(3, 3-bisphosphono-3-hydroxy-propylamino)-2-hydroxypropyl-]urazol++ +-Na2 (DDU) and 1,2,4-triglycidylurazol (TGU). The extent of bone metastases was determined by X-ray on the 5th and 10th days following tumor inoculation, as well as both microradiographically and histologically upon termination of the experiment. High dose DDU produced a clear reduction of the tumor osteolysis, but these positive results were surpassed using APD. The best results were achieved by pretreatment with APD 24 h prior to tumor inoculation.

• Authors: F Wingen, T Eichmann, C Manegold, B Krempien
• Journal: Journal of cancer research and clinical oncology (J Cancer Res Clin Oncol) Vol. 111 Issue 1 Pg. 35-41 ( 1986) ISSN: 0171-5216 [Print] Germany
• PMID: 3949849 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Diphosphonates
• Organophosphonates
• Organophosphorus Compounds
• Triazoles
• diglycidyl-(3-(3,3-bisphosphono-3-hydroxypropylamino)-2-hydroxypropyl)urazol
• anaxirone
• Pamidronate

Topics

• Animals
• Antineoplastic Agents
• Bone Neoplasms (drug therapy, metabolism, secondary)
• Carcinoma 256, Walker (drug therapy, metabolism, secondary)
• Diphosphonates (metabolism, therapeutic use)
• Male
• Organophosphonates (metabolism, therapeutic use)
• Organophosphorus Compounds (metabolism, therapeutic use)
• Pamidronate
• Rats
• Time Factors
• Triazoles (metabolism, therapeutic use)